82 -1 (29/2) 2020 — Oblokulov A.R., Elmuradova A.A., — EFFICIENCY OF ANTI-VIRUS TREATMENT OF HCV-INFECTION

EFFICIENCY OF ANTI-VIRUS TREATMENT OF HCV-INFECTION

Oblokulov A.R., Bukhara State Medical Institute.

Elmuradova A.A., Bukhara State Medical Institute.

Farmanova M.A., Bukhara State Medical Institute.

Abdullaev M.Z., Bukhara State Medical Institute.

Resume,

There were studied epidemiological features of patients with HCV-infection who were under dispensary observation in clinics located in Bukhara Region, number of patients was 319, 110 (34.5%) of them were men and 209 (65.5%) were women. Etiological diagnostics of Chronic Hepatitis C was performed by the development of RNA and genotype of HCV infection in blood serum by the method of real-time polymerase chain reaction. It was detected that 63.9% (n. 204) of the patients had first, 0.5% (n = 18) of them had second, 21.9% (n =70) – third, 0.8% (n = 27) – fourth genotype of the virus. Before antiviral therapy, in 22 (20%) in the main group of patients it was detected F0 fibrosis, so in 30 (27%) patients F1, in 36 (31.8%) patients F2 and in 23 (21%) patients F3. Fibrosis of F4 stage was revealed only in 2 (0.2%) patients. With the use of sofosbovir + ledipasvir, rapid virologic response was observed in 195 (95.6%) patients, early virological response – in 204 (100%), 200 (98%) of the patients achieved complete elimination of HCV RNA.

Key words: HCV-infection, fibroscan, sofosbovir, ledipasvir.

First page

298

Last page

300

For citation: Oblokulov A.R., Elmuradova A.A., Farmanova M.A., Abdullaev M.Z., Efficiency of anti-virus treatment of hcv-infection//New Day in Medicine 1(29)2020 298-300 https://cutt.ly/avNYvzY

List of References

  1. Нарзиев И.И., Облокулов А.А., Фармонова М.А. и др. HCV – инфекция давосида антивирустерапия самараси // Новый День в Медицине. 2019; 1(25): 274-276. http://bsmi.uz/images/ material_gallery/10-02-2020/Tib_yan_kun/1-25-2019.pdf
  2. Облокулов А.Р., Нарзиев И.И., Исмоилов У.Ю. и др. (2016) Эффективность софос бовира, а противовирусной терапии хронического гепатита С. //Российский журнал гастроэнте­рологии, гепатологии, колопроктологии. -№5 (26). -С.64
  3. Сапронов Г. В. Новые перспективы персонифицированной терапии хронического вирусного гепатита С // Г. В. Сапро­нов, Л. И. Николаева // Эпидемиология и инфекционные бо­лезни. 2013; 3: 27-36.
  4. Сюткин В. E. Новые возможности повышения эффективности противовирусной терапии больных хроническим гепатитом С. // Инфекционные болезни. 2009; 2: 55-58.
  5. Fried M.W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection // N. Engl. J. Med. 2002; 347(13): 975­982.
  6. Hadziyannis S.J. et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose // Ann. Intern. Med. 2004; 140(5): 346­355.
  7. Dore G.J., Matthews G.V., Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals // Curr. Opin. HIV AIDS. 2011; 6(6): 508-513.

file

download